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Inhibitors of the endoplasmic reticulum Ca *+-ATPase like thapsigargin (TG) and 2,5-di (rerr-butyl)-l&benzohydroquinone (rBuBHQ) cause in- 
creases in cytosolic calcium in intact human platelets resulting from prevention of reuptake. A maximal concentration of TG (0.2 ,uM) mobilized 
100% of sequestered Ca*’ compared to the action of a receptor agonist like thrombin (0. I U/ml). A maximal dose of /BuBHQ (50 PM) stimulated 
release of about 40% of intracellular calcium compared to thrombin and TG. The reduced ability of rBuBHQ to release calcium can be explained 
with an inhibitory effect on the cyclooxygenase pathway (Ki =Z 7 PM). Therefore rBuBHQ is not able to cause platelet aggregation compared to 
TG. In the presence of a cyclooxygcnase inhibitor or a thromboxane A, receptor antagonist the action of TG is identical to that observed with 
rBuBHQ. Generally, inhibition of cakium sequestration does not automatically result in platelet activation. In contrast to a receptor mediated 
activation Ca2+-ATPase inhibitors require the self-amplification mechanism of endogenously formed thromboxane A, to cause a similar response. 
We conclude that the ‘calcium store sensitive to Ca t+-ATPase inhibitors is a subset of the receptor sensitive calcium pool. 
Human platelet; Calcium pool: Thapsigargin: 2,5-Di(rert-butyl)-l,4-benzohydroquinone 
1. INTRODUCTION 
Human platelets are activated by several different 
agonists acting on specific receptors [l]. Included in the 
list of different receptor agonists thrombin and throm- 
boxane AZ can be found. Thrornboxane At i: a potent 
platelet activator which serves to amplify the response 
to weak agonists. Thromboxane is generated by the 
cyclooxygenase metabolism of arachidonic acid, itself 
released from phospholipids upon cell activation [2]. 
Thrombin, thromboxane AZ and the thromboxane 
mimetic U46619 (31 induce platelet shape change, secre- 
tion and aggregation. During receptor occupation 
phospholipase C mediates the hydrolysis of phos- 
phatidylinosittil 4,5-bisphosphate [4] to yield inositol 
1,4,5-tr?;!?csphate [5,6J and 1,2-diacylglycerol [7]. The 
release of calcium from intracellular stores by the ac- 
tion of inositol 1,4,5-trisphosphate has been 
demonstrated [H] as well as the central role of calcium 
for the activation of human platelets [9,10]. 
Inhibitors of endoplasmic reticulum Ca2+-ATPases 
are proving to be useful for studying intracel- 
lular calcium release and storage. Thapsigargin (TG) 
[ 11,121 and 2,5-di(tert-butyl)-1,4_benzohydroquinone 
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Abbrcviolions: [Ca2’]i, intracellular calcium; rBuBHQ, 2,5-di(rerr- 
Irrltylj-;,4-bcntohydroquinotle; TG, thapsigargin; U46619, I%- 
hydroxy-I I,9-[eposymethano]prosta-5,I3-dienoic acid 
OBuBHQ) [13,14] have been found to inhibit calcium 
uptake into inositol 1,4,5-trisphosphate-releasable 
pools by inhibition of the endoplasmic reticulum 
Ca”-ATPase without affecting plasma membrane 
Ca2+ transport. Therefore, both compounds cause in- 
crease in [Ca’+]i in intact cells because they release Ca” 
from intracellular stores resulting from prevention of 
reuptake. 
The results reported here demonstrate that TG and 
tBuBHQ are affecting platelet aggregation differently. 
Although both compounds release calcium, only TG 
causes a full platelet activation. In contrast to TG, 
tBuBHQ has some inhibitory side effects on platelet 
cyclooxygenase. However, the results also indicate that 
the agonist induced calcium release is quantitatively dif- 
ferent from the effect of TG and [BuBHQ. Therefore, 
we must conclude that at least two different in- 
tracellular calcium pools exist in human platelets. 
2. MATERIALS AND METHODS 
2.1 . Materials 
U46619 was purchased from Paesel, Frankfurt, Germany, throm- 
bin was bought from Hoffmann-La Roche. Basel, Switzerland and 
arachidonic acid was delivered by Larodan. MaIma, Sweden. 
Radiochemicals were obtained from Du Pont, Dreieich, Germany. 
Prostacyctin and BW 755C were purchased from Sigma, 
Deiscnhofen, Germany. Thapsigargin was ordered from Gibco, Eg- 
genstein, Germany; rBuBHQ was delivered by Cnlbiochem, 
Frankfurt, Germany and sulotroban (BM 13177) was ordered from 
Boehringer Mannheim, Mannheim, Germany. AII other materials 
were as previously described [t 51 or were obtained in the highest grade 
of p’3;if\,’ available from local commercial sources. 
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2.2. Preparation of platelet-rich plasma and washed human platelets 
Preparation of platelet-rich plasma and suspensions of washed 
human platelets were mainly carried out as previously outlined [IS]. 
Briefly, titrated whole blood was centrifuged at 200 x g for 20 min 
and platelet-rich plasma was removed. After the addition of pro- 
stacyclin (100 ng/ml) platelets were pelleted at 800 x g (IO min), 
resuspended in a washing medium [15], centrifuged again and taken 
up in Tyrode-HEPES buffer. Aggregation was monitored with an 
Elvi 840 aggregometer from Logos (Milano, Italy) according to the 
method of Born (161. Platelet cyclooxygenase and lipoxygenase were 
inhibited by preincubation with lOO/tM BW 755C for 2 min before 
starting each individual experiment. Plarelet thromboxane receptor 
was blocked by preincubation wirh IO pM BMl3177 for 2 min. 
2.3. Calcium mea.wremenIs 
Calcium measurements in intact platelels were carried out as stated 
in [ 151. External calcium was adjusted by rhe addition of I mM CaClz 
or by adding EGTA. Briefly, platelets were incubated with 2pM 
fura- AM at 37°C for 40 min, washed and resuspended in the buffer 
described above. Changes in fluorescence of the fura- loaded 
platelets at the excitation wavelengths of 335 and 362 nm and emis- 
sion wavelengths above 450 nm were determined following the addi- 
tion of antagonists and agonists. The ratio of the fluorescence is a 
measure of platelet cytosolic calcium [l7]. Solvent carriers or in- 
hibitors did not affect the method. 
2.4. A rachidonic acid melabolism 
Metabolism of exogenous [ I-%]arachidonic acid (I .7 x IO’-4.5 x 
IO5 dpm/assay) was assayed using 3-5 x IO’ platelets/~J. Incubations 
were stopped after 90 s with chloroform/methanol, metabolites were 
extracted and spotted on silica gel 60 plates in order to separate the 
metabolites. Substances were localized by autoradiography and quan- 
titated by liquid scintillation counting as outlined in [15]. Different 
concenrrations of tBuBHQ were preincubated for 2 min before star- 
ting the incubation by addition of arachidznate. Results are given as 
mean -+ SD from 3 separate experiments. 
3. RESULTS AND DISCUSSION 
Platelet aggregation is a functional assay system to 
study cel1 activation. The experiments shown in Fig. 1 
demonstrate that TG is able to induce an irreversible 
platelet aggregation (Fig. 1; trace 2). A concentration 
of 0.1 ,uM TG was found to be maximally effective. 
Higher concentrations up to 2pM showed the same 
response. Thrombin, a commonly used platelet agonist 
at a concentration of 0.1 U/ml induces the same ag- 
gregatory pattern (data not shown). Therefore, our 
results using these two platelet agonists TG and throm- 
bin are similar to the observation reported by Thastrup 
[ 121. Employing ;BuBHQ a compound with the same 
mechanism of act.ion compared to TG showed a 
somewhat modified action. 
Using low concentrations of tBuBHQ (up to 2.5 PM), 
it sometimes was possible to induce a slow starting ir- 
reversible platelet aggregation (Fig. 1; trace 4). Normal- 
ly in 9 out of 10 cases it was not possible to observe any 
platelet activation by rBuBHQ at ail. Using higher con- 
centrations of tBuBHQ (10 FM; Fig. 1; trace 3) it is im- 
possible to observe any aggregation. This is consistent 
for concentrations up to 100 PM tBuBHQ (not shown). 
Inhibition of platelet cyclooxygenase by adding 100 ELM 
BW755C abolished the stimulatory effect of TG 
(Fig. 1; trace 1). Control experiments revealed that our 
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Additions : 
A: BW 755C I Ethanol 
B : Thapsigargin 1 TG I 
C : Z.S-di-(tert-butyll-l.L-benzohydroquinone(tBuBHO) 
Traces : 
BW 755C llOOpMI+ TG(O.lpM) 
Fig. I. Thapsigargin and 2,5-di(lerl-butyl)-l,4-benzohydroquinone 
affect platelet aggregation. Aggregation of washed human platelets 
was carried out as described in section 2. Concentrations of [he test 
compounds and all additions are as given in the figure. Tracvs are 
representative for at least 5 similar experiments. 
platelets indeed showed an aggregatory response 
towards arachidonic acid which was inhibited by 
BW755C. This allows us to determine the activity of 
platelet cyclooxygenase. 
Further experiments trying to induce platelet ag- 
gregation with 1 PM arachidonic acid in the presence of 
10,uM tBuBHQ were negative (data not shown). 
In order to reveal the difference between TG and 
tBuBHQ concerning platelet activation and to explore 
the inhibitory effect of tBuBHQ on arachidonic acid in- 
duced aggregation we studied platelet eicosanoid 
metabolism. Washed platelets were incubated with 
[‘4C]arachidonate in the presence of increasing concen- 
tration of tBuBHQ as described in section 2 and as 
shown in Fig. 2. 
In these experiments no aggregatory response was 
observed in any of the samples, except for the controls 
without tBuBHQ, We found a decline in cyclooxy- 
genase pathway activity (-ix& and HHT) and a COM- 
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Fig. 2. Effect of rBuBHQ on the metabolism of [I-“Clarachidonic 
acid by platelets. Suspensions of washed human platelets were 
incubated with the indicated concentrations of [BuBHQ and the 
metabolism of [ I-‘JC]arachidonate was studied as explained in section 
2. Results are expressed as cpm corresponding to each individual 
metabolite: I2-HETE, IZ-hydroxy-5,8,10.14-eicosatetraenoic acid; 
HHT, IO-hydroxyheptadecatrienoic kid; TX&. thromboxane Bz. 
pensatory rise in It-lipoxygenase activity (12-HETE). 
Half maximal inhibitory effects of tBuBHQ on platelet 
cyclooxygenase occurred around 7-10 ,uM. In contrast 
to rBuBHQ, TG does not inhibit the metabolism of 
arachidonic acid. Therefore inhibition of platelet 
cyclooxygenase by rBuBHQ prevents the self- 
amplification mechanism known to be relevant for ac- 
tivation of thrombocytes [18]. This observation gives a 
likely explanation that tl3uBHQ does not induce 
platelet aggregation and also inhibits the response 
towards arachidoni? acid. A similar situation emerges 
from the experiment seen in Fig. 1 (trace 1). If the 
transformation of arachidonic acid is inhibited, e.g. by 
BW755C, TG is also no longer able to aggregate 
platelets. It is demonstrated by using RW755C-treated 
thrombocytes, mimicking a situation where the self- 
amplification through endogenously formed thrombox- 
ane A2 is not allowed that both compounds TG and 
tBuBHQ are no longer able to cause a full activation. 
The same situation was seen when we blocked the 
thromboxane A2 receptor with BM13177 instead of 
preventing cyclooxygenase activity with BW755C, 
although the response towards thrombin is not in- 
fluenced by either BW755C or BM13 177. Therefore we 
conclude that the formation and action of endogenous- 
ly formed thromboxane A2 is absolutely required to 
cause a full activation by either TG or tBuBHQ. The in- 
hibitory effect of tEuBHQ on platelet cyclooxygenase 
thus explains why we do not observe an aggregatory 
response. 
We were now interested to correlate these observa- 
tions with the property of the compounds to release 
calcium. from intracellular stores. Experiments 
presented in Table I were carri.:d out in the presence of 
0,5 mM cxtracellular calcium. Therefore a cytos3lic 
calcium increase should represent a release from the 
dense tubular system, which comprises the lPs-releas- 
able calcium store in human platelets. 
.4ddition of thrombin causes a rapid and transient 
elevation of the intracellular calcium from a resting 
level around 50 nM to a peak maximum of nearly 
200 nM cytosolic caIcium. The peak calcium is referred 
to as 100% effect in each of the experiments. A max- 
imal effective concentration of TG shows the same 
calcium release property compared to thrombin. In- 
terestingly, tBuBHQ releases only roughly 30% com- 
pared to TG or thrombin. Higher concentrations of the 
benzohydroquinone did not further increase the 
response. Blocking the self-amplification mechanism of 
platelets by adding the thromboxane A2 receptor an- 
tagonist EM 13 177 revealed that the calcium signal of 
thrombin is nearly unaffected. In contrast to the throm- 
bin signal we noticed a marked decrease of the TG 
response in the presence of BM13 177 to about 40% 
compared to controls without the receptor antagonist. 
The tBuBHQ response was not further influenced by 
BM13177. Qualitatively the same situation emerged 
when blocking platelet cyclooxygenase with BW755C 
instead of preventing thromboxane AZ receptor activa- 
tion. These observations reflect the situation when stu- 
dying platelet aggregation. The calcium Ca’+-ATPase 
inhibitor tBuBHQ only partly releases sequestered 
calcium without showing an aggregatory response. This 
can be explained by the inhibitory activity of the hydro- 
quinone on platelet cyclooxygenase. A similar situation 
is observed when the CaZf -ATPase inhibitor TG is used 
in the presence of BW755C or BM13177. Therefore, in 
order to release the same amount of calcium from in- 
tracellular stores by a CaZ’-ATPase inhibitory com- 
pared to a receptor agonist the action of thromboxane 
A2 is necessary. A receptor agonist like thrombin which 
is activating phospholipase C and releasing IP3, thereby 
causing efflux of stored calcium, is independent on the 
Table I 
Effect of thrombin, thapsigargin and 2,5-di(rcrr-bury])-1.4-benzo- 
hydroquinone on intracellular calcium mobilization 
Additions Agonist-induced [Ca”]i increase 
(% of thrombin response) 
Thrombin (0.1 U/ml) 100 
TG (0.2 JIM) 101 4 3 
rBuBHQ (50/1M) 32 + 7 
BM 13 I77 + thrombin 91 t4 
BM13177 + TG 44*5 
B,M13177 + rBuBHQ 34 1 6 
Human platelets were loaded with fura- and intracellular calcium 
release was measured as described in section 2. The data arc given as 
the means 2 SD of 4 replicate determinations. Calcium increases are 
rcf’ctrcd to the response of thrombin, SCI as 100% control value. The 
thromboxane .A? receptor antagonist BM13177 (lO!rM) was 
prcihcubatcd for 2 min before addition of any agonist at the 
concentration given 
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activity of platelet cyclooxygenase. This indicates that 
in !he case of TG the stimulation of thromboxane 
AZ-synthesis is alone responsible for the full activation 
and calcium liberation. Generally, a Ca’+-ATPase in- 
hibitor by itself releases only part of the calcium which 
is released after receptor stimulation. Receptor- 
sensitive stores seem to be larger and/or only partially 
sensitive to the release property of Ca2+-ATPase in- 
hibitors The results could also be interpreted in a way 
that t’,; pool sensitive to Ca’+-ATPase inhibitors is a 
subset of those sensitive after receptor stimulation. 
In conclusion our findings demonstrate that 
Ca2+-ATPase inhibitors like TG and tBuBHQ, were 
both found to inhibit the calcium uptake into 
IPJ-releasable pools and differ in their potency to cause 
a release from these stores. tBuBHQ, in contrast to TG, 
inhibits platelet cyclooxygenase thereby showing no 
platelet aggregation. Care should be taken using 
tBuBHQ if the cyclooxygenase pathway is involved in a 
transduction mechanism like in platelets. In order to 
release calcium equivalent to the action of a receptor 
agonist Ca2+-ATPase inhibitors depend on the forma- 
tion of thromboxane AZ. Differences in the property of 
receptor agonists and Ca2’ -ATPase inhibitors in releas- 
ing calcium may suggest different calcium pools in 
human platelets or a dramatically different sensitivity 
of one pool towards receptor agonists on one side and 
Ca”-ATPase inhibitors like TG and rBuBHQ on the 
other side. Our further interest will be to determine the 
characteristics of the different calcium stores in human 
platelets and the functional consequences related to 
platelet activation. 
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